Alteogen and Novartis expanded their collaboration after Novartis granted exclusive rights to develop and commercialize multiple products using Alteogen’s ALT-B4 subcutaneous delivery platform. The agreement, structured through option agreements, supports a broader push into converting biologics into subcutaneous formulations—an approach meant to improve dosing convenience and potentially reduce reliance on infusion-based administration. Novartis’ platform selection reflects its strategy to optimize patient experience and widen addressable markets. ALT-B4 joins a growing delivery-technology portfolio in the industry, where formulation advances are increasingly treated as strategic assets tied to pipeline value. For biotech developers, these deals signal that delivery platforms remain central to how big pharma scales biologic franchises and manages lifecycle investments.